rss
DTB 46:49-52 doi:10.1136/dtb.2008.06.0014
  • Articles

Three new drugs for type 2 diabetes

  • Relevant BNF section: 6.1.2.3

Abstract

For many patients with type 2 diabetes mellitus, metformin plus appropriate treatment for cardiovascular risk factors form the cornerstone of drug therapy.1 However, the progressive impairment of both the secretion and action of insulin in the condition mean that high blood glucose concentrations usually worsen over time, so necessitating escalation of hypoglycaemic therapy.1 Three drugs in two new classes that act on the hormonal regulation of insulin secretion have been launched recently for use as add-in therapies in patients with type 2 diabetes: ▼exenatide (Byetta – Eli Lilly), ▼sitagliptin (Januvia – MSD), and ▼vildagliptin (Galvus – Novartis). Here we consider whether they have a role in the management of such individuals.

Footnotes

    Free sample issue

    This DTB issue is free to all users to allow everyone the opportunity to see the full scope and typical content published in the bulletin.

    View free sample issue >>

    DTB now online first!

    Sign up to receive email alerts when new content is published online before it appears in print.

    Navigate This Article